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ABSTRACT AND KEYWORDS 
 
 
 
TITLE OF THE ABSTRACT : “Comparative Study of Serum Procalcitonin Level  
  in STEMI Patients Undergoing Primary PTCA v/s  
  Thrombolysis & to Correlate with In-hospital  
  Outcomes” 
 
KEYWORDS    : Procalcitonin, ST segment elevation myocardial  
  infarction (STEMI), Primary PTCA, Thrombolysis,  
  Cardiogenic shock 
 
 
 
 
 
AIMS / OBJECTIVES: 
 We sought to determine serum Procalcitonin (PCT) variation in two main strategies 
of reperfusion in STEMI; as well as, the importance of PCT as a prognostic marker for 
various outcomes in STEMI. 
 
 
MATERIAL AND METHODS: 
This prospective observational study was planned to include consecutive STEMI 
patients undergoing primary PTCA or thrombolysis, in one of the largest tertiary care 
hospital in South India. Blood samples for measurement of PCT were collected at 
admission and at 24 hours post-admission. All the STEMI patients were treated as per 
standard protocol and guidelines. Statistical analysis was performed to determine serum 
PCT level variation in both the groups- primary PTCA and thrombolysis. Additionally, the 
association between serum PCT level with various in-hospital outcomes was determined. 
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RESULTS: 
Rise of PCT at 24 hours was significantly higher in thrombolytic group (median 
value- 0.1800 ng/ml) when compared to primary PTCA group (median value- 0.0930 
ng/ml) with significant p-value of 0.008. Also, PCT level was significantly associated with 
cardiogenic shock (median value at 24 hours- 1.5 ng/ml) and it correlated with level of 
hsCRP. PCT level at 24 hours >0.3675 ng/ml showed 80% sensitivity and 81.3% 
specificity in prediction of in-hospital mortality. Higher level of PCT at 24 hours of 
admission was associated with lower left ventricular ejection fraction and it was 
statistically significant (p value of 0.036) with correlation coefficient (Spearman‟s rho) was 
-0.214. PCT level at 24 hours (median value= 0.36 ng/ml) was significantly associated 
with TIMI flow <3 (p value of 0.017). 
 
 
CONCLUSIONS: 
 In patients of STEMI, systemic inﬂammatory response is better reflected by PCT; 
and it indirectly suggests that primary PTCA is associated with lesser systemic 
inflammatory activation in comparison to thrombolysis. It is also a potential marker of 
future risk prediction in STEMI. 
 
  
 
 
 
 
Introduction 
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INTRODUCTION 
 
Coronary heart disease (CHD) is a major burden of mortality and morbidity in 
general population. Among the whole spectrum of conditions included under CHD, acute 
coronary syndrome (ACS) especially acute STEMI is associated with high mortality. 
Among the patients of STEMI, the maximum mortality occurs in cardiogenic shock.(1) In 
the GUSTO-1trial, the incidence of cardiogenic shock was 7.2%.(2) In-hospital mortality 
in patients with cardiogenic shock remains very high (50-80%) as noticed by various 
studies.(3) 
Inflammatory response is an important feature of ACS and STEMI. STEMI with 
cardiogenic shock is considered as a condition of SIRS (Systemic inflammatory response 
syndrome).(4) Furthermore, role of inflammation is well established in all stages of 
atherosclerosis. Inflammatory response is associated with endothelial dysfunction to 
formation of atherosclerotic plaque and subsequent plaque disruption.(5) 
It is found that various acute phase reactants rise in AMI, and are associated with a 
worse short and long term outcomes. Procalcitonin (PCT) is one of such inflammatory 
markers. Role of PCT in sepsis and septic shock is well established. But it is also found 
increasing in AMI particularly when complicated by CS.(6) It is also noticed in various 
studies that high level of various inflammatory markers, including PCT are associated with 
adverse outcomes in patients of STEMI.(7) 
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Our study is planned to examine role of PCT in patients with STEMI and with two 
main modalities of treatment of STEMI- Thrombolysis and Primary PTCA. There is no 
data showing whether PCT is helpful as a prognostic marker in STEMI patients in Indian 
population, though disease burden in Indian population is very high. This study will 
provide insight into this matter. This study is intended to show importance of serum PCT 
level in the acute STEMI for early risk stratification and its clinical importance for 
prognostication. 
 
  
 
 
 
 
 
Aims and Objectives 
5 
 
AIMS AND OBJECTIVES 
 
 Primary Aim- 
 To determine serum Procalcitonin (PCT) level variation in two main strategies of 
reperfusion in STEMI (ST-segment Elevation Myocardial Infarction) - 
Thrombolysis and Primary PTCA. 
[Hypothesis: Rise in serum PCT level in patients with STEMI should be less in primary 
PTCA group in comparison with thrombolysis group] 
 Secondary Aim- 
 To correlate PCT level with outcomes of thrombolysis (whether successful or 
failed). 
 To correlate serum PCT level with in-hospital outcomes in patients of STEMI like, 
heart failure, cardiogenic shock, reinfarction and mortality. 
 To correlate PCT level with LVEF by Echocardiogram. 
 To correlate PCT level with angiographic findings like, number of vessels 
involvement, total number of significant lesions and TIMI flow. 
 To correlate PCT level with other inflammatory marker- hsCRP. 
[Hypothesis: High serum procalcitonin level in STEMI is associated with worse in-hospital 
outcomes] 
  
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
 
Global and regional burden of STEMI 
CAD is the most common cause of death in both developing and developed 
countries.(8) By 2020, CAD is expected to increase by >120% in the less developed 
countries in comparison to 30-40% in the western countries.(9) This will place a huge 
strain on healthcare resources which are already inadequate and overstretched. 
Furthermore, the spectrum of CAD in the developed countries appears to be different from 
that in the Indian population. Less than 40% of the patients with ACS present with STEMI 
in the developed.(10) On the other hand, 60% of patients with ACS present with STEMI in 
India. One of the largest prospective registry of ACS from 89 centers from 10 regions and 
50 cities in India(11), out of 20468 patients included, 12405 (60.6%) had STEMI. 
Furthermore, patients with STEMI in India were younger (mean age was 58 years) and 
most patients were from lower middle and poor socioeconomic classes (53% and 20% 
respectively). The 30-day outcome in form of mortality with STEMI was 8.6%. Similarly, 
the Kerala ACS registry(12), also showed in-hospital mortality was much more in STEMI 
(8.2%) in comparison to non ST elevation ACS (1.8% in NSTEMI and 0.9% in UA). 
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Reperfusion strategy in STEMI -current trends in India 
In patients with STEMI, the main consideration of treatment is reperfusion either 
by primary percutaneous coronary intervention (PCI) or by thrombolysis. It is now clear 
and supported by all the current guidelines that primary PCI is preferred over thrombolysis 
particularly on late presentation; and it is far superior to thrombolysis in decreasing 
dreaded complications of STEMI like cardiogenic shock.  Primary PCI re-establishes blood 
ﬂow in the culprit coronary artery by mechanically dislodging the thrombus obstructing the 
vessel and has been shown consistently superior to thrombolysis in almost all studies. In 
spite of this, thrombolysis is the preferred modality of reperfusion strategy in most parts of 
India. In CREATE registry(11), 59% of patients with STEMI received thrombolysis (out of 
that 96% patients received streptokinase as a thrombolytic agent); while primary PCI was 
given to only 8% of STEMI patients, which is much lower in comparison to developed 
countries. In the developed countries, 40% of STEMI patients underwent primary PCI; as 
observed in GRACE registry.(10) Because of poor affordability, most patients are less 
likely to get better reperfusion strategies in developing countries like India; consequently 
reported 30-day mortality is higher. 
 
Cardiogenic shock -a dreaded complication of STEMI 
 In spite of advances in reperfusion strategy in STEMI, mortality remains high 
particularly with cardiogenic shock (CS); which is one of the dreaded complications of 
STEMI. CS occurs in 5-8% of patients hospitalized with STEMI. When acute myocardial 
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infarction advances to CS, the mortality is very high at 30-day (62%) and 6-year (88%); 
while in the absence of CS it is 9% and 45%, respectively.(13) Various factors predict 
future risk of CS in acute myocardial infarction includes, old age, HTN, DM, anterior wall 
MI, multi-vessel CAD, past history of MI or HF and LBBB. Early revascularization for CS 
improves survival substantially. The SHOCK trial(14) showed the beneficial role of early 
revascularization in comparison to initial medical stabilization. Survival at the end of one 
year was 46.7% in early intervention group with 13.2% absolute survival difference. 
 SIRS (systemic inflammatory response syndrome) in CS: The index event in the 
pathogenesis of CS is the pump failure of left ventricle. Hypoperfusion of peripheral 
organs resulting from derangements in the circulatory system is the most important factor 
in CS. CS has been linked with SIRS and it is found that there is impairment of perfusion 
of intestinal tract which occurs as a part of inappropriate vasodilation in CS. This 
mechanism is responsible transmigration of bacteria and sepsis responsible for generalized 
systemic inflammatory response.(15) The longer the duration of shock, higher the risk of 
development of SIRS. It is well known that myocardial infarction is associated with 
elevation of various inflammatory markers like, CRP, IL-6, TNF-alpha etc. particularly 
when complicated with CS. It seems that there is a role of these inflammatory markers in 
the pathogenesis of the whole spectrum of AMI, while complications in AMI in turn cause 
elevation of various inflammatory markers as a part of systemic stress.(4,16) 
 
 
9 
 
Biomarkers in Acute Myocardial Infarction (AMI) 
 Broadly, biomarkers in AMI can be classified into three groups: 1) Biomarkers of 
plaque destabilization, 2) Biomarkers for diagnosis of AMI, and 2) Biomarkers for risk 
stratification and future risk prediction in AMI. Detail classification of various biomarkers 
at various stages of AMI is described below. 
 
The History of Cardiac Biomarkers- obsolete markers: 
 In 1954, Karmen et al. described aspartate aminotransferase (AST) as a first 
biomarker of myocardial infarction. AST is found in the various organs in body like heart, 
liver, brain, kidney and skeletal muscle. It is fully non-cardio specific, and today widely 
used as a marker of liver injury.(17) Subsequently, in 1960, lactate dehydrogenase (LDH) 
was found to be elevated in AMI. Five iso-enzymes of LDH were found by 
electrophoresis. LDH 1 is abundant in cardiac muscle while LDH 4 and 5 more commonly 
present in skeletal muscle. LD1:LD2 ratio when greater than 1 was considered diagnostic 
of an AMI. It is now widely known that LDH is highly nonspecific marker of myocardial 
infarction.(18) 
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Atherosclerotic 
CAD 
Vulnerable 
plaque rupture 
and thrombosis 
Myocardial 
ischemia and 
infarction 
LV remodeling, 
Heart failure 
and CS 
BIOMARKERS OF PLAQUE 
DESTABILIZATION- 
 Myeloperoxidase (MPO) 
 Pregnancy associated Plasma Protein A 
(PaPPA) 
 Soluble CD40 ligand (sCD40L) 
 Placental growth factor (PlGF) 
DIAGNOSTIC BIOMARKERS- 
 Cardiac Troponin(cTn)* 
 Creatine Kinase (CK) 
 Myoglobin 
 Ischemia modified albumin (IMA) 
 Copeptin* 
 Choline# 
PROGNOSTIC BIOMARKERS- 
 B-natriuretic peptides (BNP / NT-
proBNP) 
 C-reactive protein (CRP) and High-
sensitivity C-reactive Protein (hsCRP)
#
 
 Growth Differentiation Factor-15 (GDF-
15) 
 Heart fatty acid binding protein (hFABP)* 
 ST2 
 Procalcitonin (PCT) 
Biomarkers at various stages of AMI 
Death 
 
  
  
* Both diagnostic as well as prognostic markers 
# also markers of plaque destabilization 
11 
 
 
 
 
 
 
 
 
 
OTHER BIOMARKERS- 
 Pro-inflammatory markers 
(IL-6, TNF-alpha) 
 
 F2 isoprostanes 
 
 Mid-Regional pro-Atrial 
Natriuretic Peptide 
(MRproANP) 
 
 Mid-Regional-pro-
Adrenomedullin 
(MRproADM) 
 
 Pentraxin-3 (PTX3) 
NOVEL BIOMARKERS- 
 Neutrophil Gelatinase-
Associated Lipocalin 
(NGAL) 
 
 Fetuin-A 
 
 YKL-40 
 
 Osteoprotegerin (OPG) 
 
 MicroRNAs (MiRNA) 
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BIOMARKERS OF PLAQUE DESTABILIZATION-- 
Myeloperoxidase (MPO): 
 MPO, a metalloproteinase is a marker of plaque disruption. It is an enzyme 
produced by neutrophils and macrophages. MPO involves in generation of hypochlorous 
acid, free radicals, and reactive nitrogen species. They are associated with endothelial 
dysfunction, plaque rupture, ventricular remodelling, and reperfusion injury during AMI. 
MPO is involved in lipid oxidation in atherosclerotic plaques which facilitates formation of 
foam cells. It also associated with activation of protease cascades and promotion of 
endothelial cell apoptosis, leading to breakdown of fibrous cap.(19,20)  
 MPO has insufficient accuracy for decision making in patients with suspected ACS 
who presented within 8 hours of symptom onset.(21) Although, Brennan ML et al(22) have 
showed that MPO is a reliable marker for vulnerable plaque. MPO level rises in the serum 
very early, within 2 hours after the onset of symptoms. Among those presented with chest 
pain, baseline MPO level independently predicted the early risk of AMI, as well as the risk 
of major adverse cardiac events in next 6 months period. MPO level was consistent in 
predicting future cardiac events across the whole spectrum of ACS, including those 
patients who were negative for cTn. In fact, in the patients of ACS, plasma level of MPO 
≥350μg/L was associated with a more than 2-fold higher adjusted odds of death or new 
AMI at 6 months.(23) In another study, Mocatta et al.(24) followed 512 ACS patients for a 
period of 5 years and found that MPO >55μg/L in plasma associated with 1.8 times higher 
risk of mortality. An assay for MPO was approved by FDA in 2005 for risk assessment in 
patients presenting with chest pain. 
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 To summarize, MPO is a powerful risk marker in ACS; though future study is 
required to decide the role of MPO in directing specific therapeutic interventions. 
 
Pregnancy associated Plasma Protein A (PaPPA): 
PaPPA is a zinc metalloproteinase, originally discovered as a glycoprotein found in 
the serum of pregnant women, produced by the syncytiotrophoblasts of the placenta. 
However, it is also produced by non-placental cell types, including vascular smooth muscle 
and endothelial cells, as well as fibroblasts. PaPPA is responsible for lysis of insulin-like 
growth factor binding protein-4 (IGFBP-4), which reduces its affinity for IGF-I and -
II.(25) It is observed that PaPPA is abundantly expressed in the vicinity of plaques with 
large lipid core and cap rupture, as well as in fibrous plaques with erosion; while it is 
almost absent in stable plaques.(26) 
In patients with ACS, elevated PaPPA level (>12.6mIU/L) is linked with an 
increased risk of future AMI and death in 6 months (odds ratio 2.44). Interestingly, PaPPA 
identified a subgroup of high-risk patients, whose cTnT was negative. PaPPA level in 
plasma correlated with CRP and sCD40L, but not with cTnT.(27) PaPPA was measured at 
baseline in 3782 patients with NSTEMI in MERLIN-TIMI 36 study group patients. A cut-
off >6.0 μIU/ml at presentation identified a high risk group with higher rates of 
cardiovascular death and MI at 30 days and at 1 year.(28) Thus, PaPPA is a promising 
prognostic marker in patients of ACS. 
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Soluble CD40 ligand (sCD40L): 
 CD40 ligand (CD40L; also called CD154), a transmembrane protein, is a cytokine 
belonging to the TNF-alpha family. CD40L is up-regulated on platelets within fresh 
thrombus. Release of sCD40L occurs by activated platelets and stimulated lymphocytes 
from the site of plaque rupture and thrombus formation in atherosclerotic coronary artery. 
Concentrations of sCD40L can be determined using a commercially available enzyme 
immunoassay.(29) 
 Serum levels of sCD40L were estimated in 1088 patients of ACS as a part of 
CAPTURE sub-study.(30) At admission sCD40L level >5.0μg/L was significantly 
associated with an increased risk of death and AMI during six months of follow-up with 
adjusted hazard ratio of 2.71. In addition, abciximab was found to reduce risk in patients 
with increased sCD40L, but not in low sCD40L group. On the contrary, in TACTICS-
TIMI 18 study, sCD40L was not found a predictor of future MI or death in ACS 
patients.(31) It can be explained by the fact that glycoprotein IIb/IIIa receptor antagonists 
reduce the risk predicted by sCD40L and almost all the patients in this study were treated 
with tirofiban. In brief, exact role of sC40L for clinical application in ACS is still unclear 
and needs further study. 
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DIAGNOSTIC AND PROGNOSTIC BIOMARKERS-- 
Cardiac Troponin (cTn): 
Cardiac troponin is the most cardio specific biomarker. While troponin proteins are 
present in both myocardium and striated muscle, the cardiac isoforms of troponin T and I 
are highly specific to the myocardium. The troponin complex is made of 3 different 
structural proteins- troponin C, I, and T. The complex is located on the thin filament of the 
contractile apparatus and regulates the calcium dependent interaction between myosin and 
actin. Assays using specific antibodies against cardiac troponins are used in clinical 
settings. For diagnosis of myocardial infarction, the efficacy of cTnT and cTnI is 
identical.(32,33) 
cTn subunits rise in the setting of myocardial necrosis and it usually takes 2-4 hours 
after the onset of decreased oxygen to myocardial tissue. That is why initial detection of 
cTn in AMI only occurs after this latency period. Initial detection of cTn in peripheral 
circulation is due to release of cytoplasmic cTn. Subsequently, release of bounded cTn 
subunits is responsible for the persistent rise in circulation. In setting of acute STEMI, cTnI 
remains detectable for 4-7 days while cTnT for 10-14 days. Clearance of cTn occurs 
mostly by the reticuloendothelial system, though some fragmented components are 
excreted by kidney.(34,35)
 
In 2012, 3rd universal deﬁnition of myocardial infarction(36), it was proposed that 
diagnosis of AMI required biochemical evidence of necrosis and cTn was considered as the 
marker of choice. The consensus document defined that for diagnosis of AMI, elevation of 
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cTn should exceed the 99
th
 percentile of upper reference limit (URL) of the population. 
Ability to detect cTn level in peripheral circulation by different assays is dependent upon 
the level of precision of individual assay. The precision of any test is measured by the 
coefficient of variation (CV). For an ideal assay for the detection of cTn, the CV at 99
th
 
percentile of URL should be ≤10% as per the consensus document. Any assay with CV 
>20% should not be used. 
Impact of Improved Sensitivity Troponin Assays: Previously used commercial 
cTn assays do not fulfill criteria of required level of precision as suggested by expert 
consensus. That led to development of new generation of highly sensitive assays, with a 
10- to 100-fold lower limit of detection of cTn. Though highly sensitivity assays are 
associated with improved sensitivity and even able to detect very minute area of 
myocardial infarction, the specificity is reduced.(37) 
It is clear that cTn is highly specific to any damage to myocardium, but it cannot 
differentiate systemic causes from primary coronary pathology responsible for the same. 
There are numerous clinical situations other than ACS, which are associated with non-
ischemic myocardial damage resulting in elevation of cTn; like, coronary spasm, tachy- 
and brady-arrhythmias, myocarditis, Takotsubo cardiomyopathy, hypertrophic 
cardiomyopathy, acute aortic dissection, hypertension, cardiac ablation procedures, cardiac 
pacing, and cardioversion. Moreover, systemic conditions like, sepsis, renal failure, severe 
respiratory failure, pulmonary embolism, severe anemia, stroke etc. also result in cTn 
elevation.(36,38) 
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To differentiate acute myocardial infarction from other systemic conditions 
associated with elevation of cTn, it is important to keep 2 things in mind while interpreting 
the value of cTn. First, the higher the absolute value of cTn at admission in patients with 
suspected AMI, the higher the probability that it is AMI. Second, the larger the rise in cTn 
within the first few hours associated with the higher probability of AMI. The National 
Academy for Clinical Biochemistry has recommended changes in cTn of  ≥20% from the 
elevated baseline values for the diagnosis of AMI in end-stage renal disease.(39) 
 
Creatine Kinase (CK): 
 Creatine kinase is involved in conversion of creatine to phosphocreatine, which is 
used by muscle tissue for the generation of ATP. It has 2 subunits, combined to generate 3 
iso-enzymes: CK-BB (CK-1) which is found in smooth muscles and brain tissue, CK-MB 
(CK-2) which is specific to cardiac myocytes, and CK-MM (CK-3) present in all 
sarcomeric muscles.(40) Skeletal muscles contain almost 98% CK-MM and only a small 
amount of CK-MB (about 2%). While human myocardium contains relatively high amount 
of CK-MB, around 20% of the total myocardial CK.(41) 
 Kinetic studies have shown that CK-MB is detectable 4-8 hours after the first onset 
of myocardial ischemia and peaks at 18-24 hours post MI, normalized in 48 to 72 hours. 
As CK-MB level returns to baseline earlier than cTn, it is a very useful biomarker for the 
detection of re-infarction.(41) CK-MB is less specific cardiac marker in comparison to 
cTn. CK-MB rise can be present in various non-cardiac conditions also like, surgery, 
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chronic and acute muscle disease, chest trauma, asthma, pulmonary embolism, 
hyperventilation, head trauma and hypothyroidism.(42) 
 CK-MB results can be analyzed by two ways: 1) absolute activity (U/L) or mass 
concentration (ng/mL) and 2) Relative index. The relative index is a percentage of total CK 
and measured as: CK-MB (activity / mass) × 100 / total CK (activity). It is proposed that 
elevated relative index (RI) >3.5% is an indicator of myocardial infarction rather than 
skeletal muscle pathology.(43) CK-MB mass assays are much more sensitive and specific 
in comparison to CK-MB activity. They are based on utilization of anti-CK-M and anti-
CK-B monoclonal antibodies.(17) 
In fact, CK-MB has iso-enzyme: CK-MB 1 and CK-MB 2. Cardiac myocyte 
contains only CK-MB2, while CK-MB1 is present in plasma. Normally there is 
equilibrium between the two. A ratio of CK-MB2 to CK-MB1 ≥1.5 is suggestive of 
myocardial infarction. With the introduction of CK-MB mass assays, CK-MB isoforms are 
no longer in use nowadays.(44) 
 
Myoglobin: 
 Myoglobin is an iron- and O2-binding protein found in the myocytes. Myoglobin 
increases within 1-3 hours after myocardial infarction, usually peaks within 6-9 hours, and 
normalizes in 24 hours of the index event. Among all the traditional markers currently used 
in diagnosis of AMI, myoglobin is the earliest biomarker to rise.(45,46) Though myoglobin 
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lacks specificity, it is highly sensitive and that is why it is useful as an early marker of AMI 
with high negative predictive value.(47) 
 
Ischemia modified albumin (IMA): 
 The amino terminal of plasma albumin normally has an affinity to some heavy 
metal ions. Due to ischemia, generation of free radicals alter the albumin resulting in loss 
of its ability to bind with heavy metals. This modified albumin (IMA) can be measured by 
albumin cobalt-binding (ACB) test.(48) As we know that cTn will rise in plasma only 
when myocardial necrosis occurs, but not if only reversible ischemia is present. IMA can 
be used to detect acute myocardial ischemia even prior to the necrosis. Unlike cTn, IMA 
level increases in blood within 1
st
 hour of onset of ischemia, much ahead of the onset of 
myocardial necrosis. Subsequently its level normalizes within 6-12 hours. In comparison to 
cTn, IMA is much more sensitive but specificity is very low.  It should be kept in mind 
while interpretation of IMA measurement that serum albumin concentration is variable 
among individuals due to various reasons.(49) 
Meta-analysis of IMA to rule out ACS in the emergency department showed that 
when used with ECG and cTn in patients presenting with chest pain (within 3 hours of 
duration), IMA had negative predictive value of 97.1% for excluding ACS. IMA has 
already been licensed by the FDA for diagnosis of suspected myocardial ischemia.(50) 
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Copeptin: 
 Copeptin is the C-terminal part of the pro-hormone of vasopressin (AVP). 
Elevation of both vasopressin and copeptin occur in various stressful systemic conditions 
causing SIRS.(51) In patient with AMI, copeptin level reaches at peak usually in 4-6 hours, 
which is followed by a plateau level and it lasts for 3-5 days. In a study by Reichlin T et 
al., when combined with cTn, copeptin had very high negative predictive value (99.7%) to 
rule out myocardial infarction. Copeptin cut-off used was 14pmol/L. However, it is 
observed that copeptin does not rise in unstable angina (UA), probably because UA does 
not induce high level of systemic stress in comparison to AMI.(52)  
 Copeptin also considered as a prognostic marker in AMI. The LAMP Study(53) 
documented copeptin as an independent predictor of death or heart failure at 60 days in 
patient of myocardial infarction. A multicenter CHOPIN Trial(54), included 1967 patients 
presenting with chest pain of 6 hours of duration. Adding copeptin to cTnI not only 
improved negative predictive value to rule out AMI, but AMIs not detected by the initial 
cTnI alone were picked up with copeptin >14pmol/L in 72% of patients. 
In conclusion, addition of copeptin cut-off to cTn in patients with chest pain 
drastically improves sensitivity and negative predictive value. But copeptin is unable to 
differentiate UA from non-cardiac chest pain. 
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Heart fatty acid binding protein (hFABP): 
 The major role of hFABP in human heart is in fatty acid transport and metabolism. 
Although it is expressed extensively in the myocardium, small quantities also can be found 
in skeletal muscle, kidney and brain. Following AMI, hFABP elevated in plasma within 3 
hours and normalize within 12-24 hours; thus, the plasma kinetics of hFABP is quite 
similar to those of myoglobin. This makes both myoglobin and hFABP useful biochemical 
markers for the early diagnosis of AMI.(55) Though, hFABP cannot be used alone to rule 
out the diagnosis of AMI. An analysis of 6 studies revealed that the positive and negative 
predictive value of hFABP for the diagnosis of AMI is 65.8% and 82% respectively.(56) In 
another study, for the diagnosis of AMI within the first 4 hours of symptoms, hFABP was 
found to have greater sensitivity in comparison to cTn (86% vs. 42%, p<0.05) but lacked 
specificity. Combining hFABP and cTn improved the sensitivity to 97%.(57) 
OPUS-TIMI 16 substudy(58) showed the prognostic value of hFABP in acute 
coronary syndrome, irrespective of cTn value. In fact, when used in combination with a 
routine measurement of cardiac troponin (12-24 hours after onset of symptoms), hFABP 
can forecast the future cardiac events and death after ACS across the range of troponin 
values in a manner that is additive to the GRACE (Global Registry of Acute Coronary 
Events) clinical risk factors.(59) In one recent study, Viswanathan et al. demonstrated that 
patients with suspected ACS with negative cTn, hFABP cutoff of 6.48µg/L was an 
independent prognostic factor of future mortality and MI at 1 year.(60) 
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 To summarize, hFABP is not as superior as other more specific biomarkers for 
diagnosis of AMI. But it is a valuable prognostic marker predicting future risk even in 
patients with negative cTn. 
 
B-natriuretic peptides (BNP / NT-proBNP): 
 BNP is a 32 amino acid neurohormone, which is synthesized and released from the 
cardiac ventricle in response to multiple stimuli including ischemia, increased wall stress, 
and dilation of the ventricles. Pro-BNP, a precursor of BNP is catalyzed into BNP and NT-
proBNP (which is the amino-terminal portion of the pro-BNP peptide). The action of BNP 
on vascular smooth muscle cells and kidney is to reduce systemic vascular resistance and 
to induce natriuresis. BNP has a short plasma half-life but NT-proBNP is much more stable 
in serum and has longer half-life.(61,62) 
 Various studies documented the role of BNP and NT-proBNP in adding valuable 
prognostic information in patients presenting with AMI.(63) The prognostic value of BNP 
was evaluated in 2525 patients presented with acute coronary syndrome in ACS-TIMI 16 
study.(61) Interestingly, the future risk of mortality, infarction and heart failure was 
predicted by baseline BNP level of more than 80pg/mL.(61) In fact, the prognostic 
information by NT-proBNP was additive to  the GRACE risk score in forecasting future 
mortality in ACS.(64) 
 Similarly, BNP level >80pg/mL in first 24 hours was the predictor of future 
mortality and heart failure events in TACTICS-TIMI 18 trial among 1676 patients of 
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UA/NSTEMI. In fact, BNP was also able to predict risk among patients with cTnI 
<0.1ng/mL. However, BNP did not identify those who might benefit from early 
revascularization procedure.(65) Subsequently, the ability of NT-proBNP to detect high 
risk ACS patients who benefit from an early revascularization was evaluated in the FRISC-
II trial. In patients with increased levels of both NT-proBNP (NT-proBNP levels in the 
upper tertile >905ng/L in men and >1345ng/L in women) and IL-6 (≥5mg/L), an early 
revascularization reduced mortality by 7.3%.(66) 
 In brief, NT-proBNP is a promising biomarker in ACS for risk stratification; but 
before acceptance into clinical use 2 issues need to be resolved- the role of NT-proBNP in 
combination with cTn and utilization of NT-proBNP in targeting therapy in ACS. 
 
C-reactive protein (CRP and hsCRP): 
 C-reactive protein (CRP) is a marker of acute inflammation and produced by liver 
in response to circulating inflammatory cytokines, mostly by IL-6. Higher sensitivity 
assays of CRP can detect even lower levels of CRP (<5mg/L).(67) Since many years, CRP 
has been involved in the inflammatory process of atherosclerosis. It has been shown that 
huge increase of CRP in AMI is the refection of SIRS secondary to large area of 
myocardial infarction.(68) It is also observed that CRP elevation may be associated with 
plaque rupture in patients of AMI.(69) 
 In patients of ACS, CRP is a prognostic biomarker and a significant predictor of 
poor outcome rather than a diagnostic marker. In a study by Suleiman M et al(70), CRP 
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level was measured within 12 to 24 hours of symptoms onset in 1044 patients admitted 
with AMI. High CRP level was significantly associated with future risk of death and 
cardiac failure. In another study, serial measurements of serum CRP levels were done to 
know the kinetics of CRP in STEMI patients. Post-MI CRP level peaked at 2-4 days, and 
then remained elevated till 8-12 weeks. The peak CRP level ≥20mg/dL was an independent 
marker of cardiac rupture, LV aneurysm formation and 1-year mortality.(71) In another 
study, in patients of myocardial infarction, first-day CRP value >15mg/L was associated 
with high risk of development of heart failure in 1
st
 week; while peak CRP >85mg/L was a 
powerful indicator of future death.(72) In fact, CRP value in first 24 hours of STEMI was a 
predictor of LV dysfunction and LV remodelling in one study.(73) 
 
Growth Differentiation Factor-15 (GDF-15): 
 GDF-15 is a member of the TGF-β cytokine superfamily, released by 
cardiomyocytes in reaction to ischemia and reperfusion.(74) The specificity of GDF-15 is 
very poor in the diagnosis of acute coronary events, so mainly it has prognostic value.(38) 
 Among patients with NSTEMI in GUSTO-IV trial, it was observed that increasing 
level of GDF-15 level correlated with increased one year mortality ( the best cutoff to 
predict future events was- 1808ng/L).(75) Similarly, prognostic role of GDF-15 in STEMI 
patients receiving fibrinolytic therapy was proven by another study. In patients with 
STEMI, one year mortality was 14% when GDF-15 was >1800ng/L.(76) GDF-15 is also 
an important tool to identify high risk patients and helpful in therapeutic decision making 
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in patients with UA/NSTEMI, as observed in FRISC-II study(77). When GDF-15 level 
≥1200ng/L, early intervention significantly decreased the risks of future MI and mortality; 
while there was no benefit of early invasive strategy when its level was <1200ng/L, even 
though cTnT level >0.01µg/L. 
 
ST2: 
 ST2 is a member of the interleukin (IL)-1 receptor family. It exists in two forms- a 
trans-membrane receptor (ST2L) and a soluble decoy receptor (sST2). The ligand of ST2 is 
IL-33, which is protective and has been shown to exert anti-hypertrophic and anti-fibrotic 
effects in heart. Soluble ST2 is a decoy receptor for IL-33 and counteracts its protective 
effects. Abnormalities in ST2 signaling is found responsible for cardiac hypertrophy, 
fibrosis, and ventricular dysfunction.(78) More recently, a highly sensitive ELISA for sST2 
has been developed (Presage ST2 Assay), this assay is FDA approved. An upper reference 
limit of 35ng/ml has been set for this assay; 95% of normal subjects are below this 
threshold value. sST2 value can increase in pneumonia and chronic obstructive pulmonary 
disease, but unlikely affected by body mass index or renal insufficiency.  Patients with 
sepsis exhibited highly elevated sST2 values.(79) 
 Shimpo et at.(80) evaluated role of sST2 in 810 patients with AMI in the TIMI 14 
and ENTIRE-TIMI 23 sub study. Similarly, CLARITY-TIMI 28 study investigated the role 
of sST2 in 1239 patients of STEMI.(81) Both the studies showed that high sST2 level is an 
independent prognosticator of in-hospital and 30 days death as well as future risk of 
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cardiac failure. sST2 level starts rising in serum within few hours of index event and 
reaches at peak at 12 hours. Similarly the role of sST2 in NSTEMI was evaluated among 
4426 patients enrolled in MERLIN-TIMI 36 trial. Though sST2 was only weakly 
correlated with troponin and BNP levels, high sST2 was strongly correlated with high risk 
of cardiovascular mortality and heart failure at 30 days and 1 year (sST2 cut-off used was 
35µg/L).(82) 
 To summarize, ST2 is an emerging novel biomarker predicting future risk in 
patients of AMI. Because of its plausible role in ventricular remodeling, modification of 
ST2 and its associated pathways can be a target for future therapeutic approach. 
 
PROCALCITONIN (PCT): 
 Procalcitonin is a protein of 116 amino-acids with molecular weight of 13 kDa, was 
discovered by Moya et al. in 1975. It is a precursor of calcitonin produced by C-cells of the 
thyroid gland. Normally in healthy subjects, the level of PCT is undetectable.(83) 
 PCT elevation during inflammation is not produced in C-cells of the thyroid. The 
probable site of production of „inflammatory PCT‟ is the neuroendocrine cells in the lungs 
or intestine. Kinetics of PCT was studied after the administration of endotoxin; a powerful 
inducer of production of PCT. It was observed that rise of PCT occurred after 3-6 hours 
and reached a peak at 6-8 hours. PCT remained elevate for longer duration (12-48 hours), 
due to its long half-life. PCT rises after the elevation of TNF and IL-6, but before the rise 
of CRP.(84) After shock or tissue injury (i.e. surgery, trauma, burn) or infections and 
27 
 
sepsis, PCT mRNA expression has been documented in human extra-thyroidal tissues. 
Thus, PCT is considered as an acute-phase marker and rise of PCT in circulation can be 
considered as a part of the generalized inflammatory response.(85) 
Over the past decade, it has become clear that inflammation interplays a significant 
role in the pathogenesis of AMI; starting from atherosclerotic plaque formation to plaque 
disruption in coronaries, as evident by striking rise of numerous inflammatory markers 
after AMI.(86) Cardiogenic shock is a condition of systemic inflammatory response 
syndrome (SIRS), rise of PCT is seen along with various other inflammatory markers like 
IL-6, TNF-alpha and CRP.(15) Though, rise of PCT occurs in AMI, particularly when 
complicated by CS, rise of PCT with septic shock is much more. PCT level in circulation 
increased upto 72 to 135ng/mL in septic shock, in comparison to around 1ng/mL in 
cardiogenic shock in one study.(87) 
Kinetic of PCT in patients with CS following AMI: In a study by Kafkas et 
al.(88), serum levels of PCT along with various other biomarkers were measured serially in 
patients with AMI. PCT was first detected in serum 2-4 hours after the onset of the 
symptoms and reached a plateau in 12-24 hours. While CRP levels showed an increase in 
plasma after the 3-6 hours, it reached a peak at approximately 48-72 hours. Thus, rise of 
PCT is much earlier in comparison to CRP in AMI. 
PCT values increased remarkably in complications of myocardial infarction like, 
cardiogenic shock, while it remained undetectable in uncomplicated ACS where systemic 
inflammatory response is much less.(89,90) In the contrary, Senturk et al. documented that 
high PCT levels was present in ACS, but did not correlate with severity of coronary artery 
28 
 
disease and early prognosis.(91) In another study, it was observed that even in the absence 
of sepsis, PCT level can rise >2ng/mL in cardiogenic shock.(92) High admission values of 
PCT was associated with increased in-hospital and 1 year mortality in patients with 
AMI.(93) A larger study by Kelly et al revealed an adverse outcome in subjects with PCT 
above the median value. PCT was associated with LV dysfunction and remodeling as 
well.(94) 
Finally, PCT can also be a prognostic tool in stable coronary artery disease. 
AtheroGene Study evaluated role of PCT in 2131 patients with stable CAD. PCT 
independently predicted future risk of cardiovascular death in such patients, though it was 
not superior to CRP for prediction of outcome.(95) 
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MATERIALS AND METHODS 
 
This prospective observational study was done in 102 consecutive patients of acute 
ST elevation myocardial infarction (STEMI) admitted between December 2012 to April 
2013 in the chest pain unit of a tertiary care center in South India. 
 
INCLUSION CRITERIA: 
Patients with age more than 18 years, who presented with STEMI and eligible for 
reperfusion therapy, were included in the study after taking informed consent. Acute 
STEMI was diagnosed based on universal deﬁnition of myocardial infarction. 
 
EXCLUSION CRITERIA: 
 Patients not willing to participate in the study 
 Age ≤18 years 
 STEMI patients in whom thrombolysis or primary PTCA not done according to 
guidelines like, late presentation 
 STEMI patients who underwent Pharmacoinvasive PTCA 
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 Patients with acute or chronic inflammatory diseases, those with bacterial infections 
and sepsis, and patients taking steroidal or non-steroidal anti-inflammatory drugs 
were excluded from the study 
 Patients with significant underlying other systemic disorders like chronic renal, 
hepatic, or respiratory failure and malignancy 
 Patients who underwent any surgery in the last 4 weeks before STEMI 
 Pregnancy 
 
A detailed history and physical examination pertaining to cardiovascular system 
was performed in all STEMI patients eligible for the study.  All the patients were treated as 
per the STEMI guidelines. They underwent either of 2 main modalities of reperfusion 
therapy of STEMI- primary PTCA or thrombolysis. All of them were offered primary 
PTCA in view of its superiority over thrombolysis. Patients not willing for primary PTCA 
underwent thrombolysis. All patients were given routine pharmacotherapy according to 
standard protocols and guidelines. Routine blood examinations, ECG and chest x-ray were 
taken. Standard transthoracic echocardiography was performed on all patients. Any 
complications of STEMI were treated as per standard guidelines. 
After taking informed consent, blood samples for measurement of Procalcitonin 
(PCT) were collected at admission and at 24 hours after admission. Apart from PCT, 
another inflammatory marker hsCRP was also measured at admission and at 24 hours after 
admission for comparison. All the patients were followed for the entire duration of hospital 
stay for any major cardiac events or any complications associated with STEMI.  All 
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STEMI patients were divided in two groups according to reperfusion strategy into- primary 
PTCA group and Thrombolysis group. Variation of serum PCT level was compared 
between these two groups. 
We also compared serum PCT level to various in-hospital outcomes in patients 
with STEMI like- 
(i) Hemodynamic deterioration during hospitalization [deﬁned as the occurrence of a ﬁnal 
maximum Killip-Kimball class]. 
(ii) Progression to cardiogenic shock [clinically defined as peak systolic pressure <90 
mmHg for >30 min after correction of hypovolemia, hypoxemia and acidosis or need for 
vasopressor and/or inotropic therapy along with signs of organ hypoperfusion such as 
oliguria/anuria, changes in mental state or elevated serum lactate concentrations 
(>2.0mmol/L) along with clinical evidence of elevated LV filling pressure (like pulmonary 
congestion on physical examination or chest x-ray)]. 
(iii) Development of reinfarction [defined as acute MI (in the same arterial territory) that 
occurs within 28 days of primary event (in our study- before discharge)]. 
(iv) In-hospital mortality. 
(v) LVEF by Echocardiogram. 
(vi) Failure of thrombolysis [defined as persistence of angina OR <70% ST-segment 
resolution in ECG at 60-90min OR hemodynamic and/or electric instability]. 
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(vii) Angiographic findings like, number of vessels involvement, total number of 
significant lesions and TIMI flow. 
 
DATA SOURCES / MEASUREMENT: 
 Serum PCT was measured by homogenous immunoassay by TRACE (Time 
Resolved Amplified Cryptate Emission) method. Machinery used for the same was 
BRAHMS kryptor compact machine. 
 Detection limit of serum PCT- 0.02 ng/ml and Measuring range upto- 40 ng/ml. 
 
STATISTICAL METHODS: 
 Continuous variables were presented as proportions. Quantitative variables were 
expressed as mean and standard deviation if normally distributed or median and 
25
th
/75
th
 interquartile range for skewed (|skewness| >1) deviation. 
 The association of PCT levels with categorical variables was assessed using the 
paired t-test or Mann–Whitney U test for non-parametric data and with continuous 
variables using Pearson‟s correlation coefficient. P-value was calculated by 
Pearson's chi-squared test for categorical variables [for n (%)], t-test and ANOVA 
for parametric variables and Mann–Whitney U test and Kruskal-Wallis H Test for 
nonparametric variables. Results were evaluated within 95% confidence interval 
and P value <0.05 was accepted as significant. 
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Detailed diagrammatic Algorithm of the study: 
 
 
 
STEMI patients, age 
>18 years, admitted in 
chest pain unit 
Eligible for 
reperfusion therapy 
Primary PTCA 
group 
 
Exclusion: 
 Not willing 
 Not eligible for reperfusion 
therapy according to 
guidelines 
Exclusion: 
 Pharmacoinvasive PTCA 
 Chronic inflammation / 
infection 
 Significant comorbidity / 
malignancy 
 Pregnancy 
 Surgery in last 4 weeks 
Thrombolytic 
group 
 
 Serum Procalcitonin measurement at 
admission and at 24 hours 
 Follow up till discharge for various 
outcomes 
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RESULTS 
 
[A] BASELINE CHARACTERISTICS 
 Total 102 consecutive patients with STEMI were enrolled over a period of 5 
months. Out of that, 51 patients underwent primary PTCA and 51 patients received 
thrombolysis (50 patients got Streptokinase while 1 patient got Tenecteplase). 
Table-1 Baseline characteristics of study population according to two main treatment 
groups 
 
TOTAL 
(n=102) 
Pri-PTCA 
(n=51) 
TLT 
(n=51) 
p-value 
Age (years) 55.6±12.4 55.3±13 55.9±11.8 0.794 
Male 87 (85.3%) 45 (88.2%) 42 (82.4%) 0.402 
HTN 36 (35.3%) 17 (33.3%) 19 (37.3%) 0.679 
DM 47 (46.1%) 22 (43.1%) 25 (49%) 0.551 
Smoking 45 (44.1%) 23 (45.1%) 22 (43.1%) 0.842 
WP (hours) 4.5 (3/7.25) 4.5 (2.5/8) 4.5 (3/4.5) 0.922 
PR (/min) 80 (71.5/96) 80 (70/90) 80 (72/100) 0.186 
SBP (mmHg) 120 (106/140) 120 (100/140) 120 (110/120) 0.736 
TIMI risk score 3 (2/5) 3 (2/5) 3 (2/5) 0.550 
[HTN- hypertension, DM- diabetes, WP- window period, PR- pulse rate SBP- systolic BP] 
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* WP, PR, SBP, TIMI risk score in Table-1 mentioned median value and 25
th
 / 75
th
 
interquartile range. 
 
Figure-1 Distribution of baseline TIMI risk score among two main treatment groups 
 
 
Table-1 and Figure-1 showed distribution of various variables which can affect the 
outcomes in STEMI. There was no significance difference of distribution of risk factors 
(including TIMI risk score) among the two main treatment groups. 
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Table-2 Distribution of types of STEMI (based on region involvement) among two 
main treatment groups 
ECG 
TOTAL 
(n=102) 
Pri-PTCA 
(n=51) 
TLT 
(n=51) 
p-
value 
AW 58 (56.9%) 28 (54.9%) 30 (58.8%) 
0.979 
AW + qRBBB 10 (9.8%) 5 (9.8%) 5 (9.8%) 
IW ± RV 21 (20.6%) 11 (21.6%) 10 (19.6%) 
IW ± PL 13 (12.7%) 7 (13.7%) 6 (11.8%) 
[AW- anterior wall, IW- inferior wall, RV- right ventricle, PL- posterolateral] 
 As shown in Table-2, the distribution of various types of STEMI was equal among 
two main treatment groups (p value 0.979). 
 
 Findings of various blood result parameters were also almost identical in both the 
treatment groups (Table- 3). 
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Table-3 Various blood results among two main treatment groups 
 
TOTAL 
(n=102) 
Pri-PTCA 
(n=51) 
TLT 
(n=51) 
p-value 
Hb (g%) 14±2.4 14.5±2.5 13.5±2.3 0.055 
TLC (/cumm) 12607±4463 12755±3739 12463±5110 0.751 
RBS (mg%) 165 (127/229) 155 (120/216) 181 (131/263) 0.230 
HbA1C (%) 6.4 (5.8/8.1) 6.4 (5.8/8) 6.6 (5.8/8.3) 0.688 
Creatinine (mg%) 1.26±0.3 1.22±0.27 1.31±0.36 0.193 
eGFR
*
 65±19 67±17 63±21 0.331 
TC (mg%) 175 (135/206) 168 (139/200) 176 (132/222) 0.443 
TG (mg%) 103 (76/181) 99 (75/166) 127 (87/200) 0.122 
HDL (mg%) 33 (30/41) 33 (29/42) 34 (30/41) 0.736 
LDL (mg%) 117 (86/144) 112 (87/138) 117 (82/145) 0.666 
 (*eGFR in mL/min/1.73m2 was calculated by CKD-EPI formula) 
[Hb- hemoglobin, TLC- total leukocyte count, RBS- random blood sugar measured at the 
time of admission, TC- total cholesterol, TG- triglyceride, HDL- high density lipoprotein, 
LDL- low density lipoprotein] 
 
 
 
 
38 
 
[B] VARIATION OF PCT (and hsCRP) LEVEL IN STEMI 
 We compared PCT level along with hsCRP (on admission and at 24 hours value) 
among STEMI patients based on primary PTCA and thrombolysis group (Table-5). In all 
the patients of STEMI, serum Procalcitonin level increased significantly at 24 hours after 
admission. At admission, the median value of PCT was almost identical in thrombolytic 
group (0.0470 ng/ml) and primary PTCA group (0.0583 ng/ml) [in fact PCT values at 
admission in thrombolytic group was lower in comparison to PTCA group with p value of 
0.086]. While rise of PCT at 24 hours was significantly higher in thrombolytic group 
(0.1800 ng/ml) in comparison to primary PTCA group (0.0930 ng/ml). Similarly, hsCRP 
also showed the same rise at 24 hours in TLT group (Table-4, Figure-2a and 2b). 
Table-4 Variation of PCT and hsCRP among two main treatment groups 
[PCT and hsCRP values shown as median value and 25
th
/75
th
 interquartile range] 
 
TOTAL 
(n=102) 
Pri-PTCA 
(n=51) 
TLT 
(n=51) 
p-
value
*
 
PCT-OA 
0.0533 
(0.0360/0.0814) 
0.0583 
(0.0405/0.0856) 
0.0470 
(0.0300/0.0760) 
0.086 
PCT-24 
0.1403 
(0.0733/0.2840) 
0.0930 
(0.0617/0.1987) 
0.1800 
(0.1000/0.4200) 
0.008 
hsCRP-OA 3.97 (1.58/8.09) 3.83 (1.94/6.78) 4.12 (1.43/9.84) 0.995 
hsCRP-24 34.10 (18.45/57.35) 21.30 (8.23/42.63) 45.50 (24.10/69.50) <0.001 
[PCT-OA and PCT-24 = Procalcitonin level at the time of admission and at 24 hours 
respectively. hsCRP-OA and hsCRP-24 = hsCRP level at the time of admission and at 24 
hours respectively. PCT values in ng/ml. hsCRP values in mg/L.] 
(*p-value was measured by Mann–Whitney U test) 
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Figure-2a Distribution of PCT (at admission and at 24 hours) among two main 
treatment groups 
 
 
 
Figure-2b Distribution of hsCRP (at admission and at 24hours) among two main 
treatment groups 
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[C] VARIATION OF PCT (and hsCRP) LEVEL IN TLT GROUP 
 Out of 51 patients who received thrombolytic therapy, successful thrombolysis 
occurred in 18 patients and in 33 patients it was unsuccessful. We analyzed PCT and 
hsCRP level in both the groups (Table-5). Though at admission, values of both the 
inflammatory markers showed no difference; at 24 hours there was significant rise of both 
PCT and hsCRP in patients with failed thrombolysis in comparison to patients with 
successful thrombolysis. 
Table-5 Variation of PCT and hsCRP in Thrombolysis group based on success/failure 
 
Total 
(n=51) 
Successful TLT 
(n=18) 
Failed TLT 
(n=33) 
p-value 
PCT-OA 
0.0470 
(0.0300/0.0760) 
0.0390 
(0.0260/0.0613) 
0.0500 
(0.0325/0.0885) 
0.112 
PCT-24 
0.1800 
(0.1000/0.4200) 
0.1015 
(0.0650/0.1578) 
0.2590 
(0.1435/0.5365) 
0.001 
hsCRP-OA 4.12 (1.43/9.84) 2.64 (1.19/7.08) 4.79 (1.66/10.37) 0.265 
hsCRP-24 45.50 (24.10/69.50) 32.40 (20.55/48.63) 51.50 (38.05/92.70) 0.005 
 
 As shown in Figure-3a, distribution of PCT level at admission in both successful 
and failed thrombolysis was identical (p value 0.112). While at 24 hours (Figure-3b), 
higher PCT level was observed in the failed thrombolysis group with p value of 0.001 by 
Wilcoxon–Mann–Whitney test. [Figure-3a and 3b prepared by Log-Scaled Histograms.] 
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Figure-3a and 3b Variation of PCT (at admission and at 24hours) in TLT group 
(based on success/failure of thrombolysis) 
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[D] COMPARISON BETWEEN PRIMARY PTCA and TLT GROUPS 
 Subsequently, we compared level of PCT and hsCRP between primary PTCA and 
successful TLT patients as well as between primary PTCA and failed TLT patients (Table-
6). There was no difference in distribution of both inflammatory markers between primary 
PTCA and successful TLT patients. But there was significant rise of PCT and hsCRP at 24 
hours in failed TLT patients in comparison to primary PTCA group. 
Table-6 Variation of PCT and hsCRP among PTCA and TLT groups 
 
(I) Pri-PTCA 
(n=51) 
(II) Successful TLT 
(n=18) 
p-value 
(I vs. II) 
(III) Failed TLT 
(n=33) 
p-value 
(I vs. III) 
PCT-
OA 
0.05833 
(0.0405/0.0856) 
0.0390 (0.0260/0.0613) 0.015 
0.0500 
(0.0325/0.0885) 
0.478 
PCT-
24 
0.0930 
(0.0617/0.1987) 
0.1015 (0.0650/0.1578) 0.854 
0.2590 
(0.1435/0.5365) 
<0.001 
hsCRP
-OA 
3.83 (1.94/6.78) 2.64 (1.19/7.08) 0.424 4.79 (1.66/10.37) 0.586 
hsCRP
-24 
21.30 
(8.23/42.63) 
32.40 (20.55/48.63) 0.087 
51.50 
(38.05/92.70) 
<0.001 
 
 These findings also depicted in Figure-4a and 4b by Log-Scaled Histograms. 
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Figure-4a and 4b Variation of PCT level at 24hours in Primary PTCA and TLT 
(successful and failed) groups 
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[E] CORRELATION OF PCT and hsCRP WITH IN-HOSPITAL 
OUTCOMES 
Total 12 patients developed cardiogenic shock (CS). CS occurred in 5 patients who 
underwent primary PTCA and 7 patients who received thrombolytic therapy. Total in-
hospital mortality was 11; out of that, 4 occurred in primary PTCA and 7 occurred in 
thrombolytic group. LVEF was lower in TLT group in comparison to primary PTCA 
group, and it was statistically significant (p= 0.036 by t test). 
 
Table-7 In-hospital outcomes among two main treatment groups 
 
TOTAL 
(n=102) 
Pri-PTCA 
(n=51) 
TLT 
(n=51) 
p-value 
Killip 
class 
I 72 (70.6%) 38 (74.5%) 34 (66.7%) 
0.465 
≥II 30 (29.4%) 13 (25.5%) 17 (33.3%) 
Cardiogenic 
shock 
12 (11.8%) 5 (9.8%) 7 (13.7%) 0.539 
LVEF (%) 41.8 ± 6.7 43.2 ± 6.8 40.4±6.4 0.036 
Death (In-
hospital) 
11 (10.8%) 4 (7.8%) 7 (13.7%) 0.338 
LVEF- left ventricle ejection fraction 
 
 
45 
 
We compared PCT and hsCRP level with development of cardiogenic shock in 
patients of STEMI (Table-8). At admission there was no difference in level of both the 
inflammatory markers among patients who developed or didn‟t develop CS subsequently 
during hospital stay. But at 24 hours there was significant rise of both the inflammatory 
markers in patients who developed CS (Figure-5a and 5b). 
Table-8 PCT and hsCRP in Cardiogenic Shock (CS) 
 
TOTAL 
(n=102) 
No CS 
(n=90) 
CS 
(n=12) 
p-
value 
PCT-OA 
0.0533 
(0.0360/0.0814) 
0.0540 
(0.0380/0.0770) 
0.0500 
(0.0279/0.1400) 
0.843 
PCT-24 
0.1403 
(0.0733/0.2840) 
0.1380 
(0.0700/0.2580) 
1.500 
(0.4400/6.3000) 
0.001 
hsCRP-OA 3.97 (1.58/8.09) 3.15 (1.57/6.94) 5.93 (2.98/20.43) 0.97 
hsCRP-24 34.10 (18.45/57.35) 31.20 (17.80/50.80) 100 (69.5/134.00) 0.001 
p-value calculated by Mann–Whitney U test with alpha level of 0.05 and confidence level 
95%. 
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Figure-5a Distribution of PCT in cardiogenic shock 
 
Figure-5b Distribution of hsCRP in cardiogenic shock 
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 Similarly, we also compared association of PCT and hsCRP level with in-hospital 
mortality (Table-9). The admission value of PCT and hsCRP was identical among patients 
who survived or died during hospital stay. But the 24 hours value of both the inflammatory 
markers was significantly higher among patients who died in comparison to those who 
survived (Figure-6a and 6b). 
 
Table-9 Association of PCT and hsCRP with in-hospital mortality 
 
TOTAL 
(n=102) 
Survived 
(n=91) 
Death 
(n=11) 
p-
value
* 
PCT-OA 
0.0533 
(0.0360/0.0814) 
0.0560 
(0.0380/0.0814) 
0.0400 
(0.0240/0.1100) 
0.476 
PCT-24 
0.1403 
(0.0733/0.2840) 
0.1392 
(0.0700/.2612) 
0.4400 
(0.2375/3.9500) 
0.022 
hsCRP-OA 3.97 (1.58/8.09) 3.09 (1.57/6.91) 5.43 (4.30/21.00) 0.085 
hsCRP-24 34.10 (18.45/57.35) 31.3 (18.2/51.5) 100 (84.75/16.50) 0.003 
*p-value calculated by Mann–Whitney U test with alpha level of 0.05 and confidence level 
of 95%. 
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Figure-6a PCT and in-hospital mortality 
 
Figure-6b hsCRP and in-hospital mortality 
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We plotted ROC curves to get the cut-off values of PCT and hsCRP in correlation 
with CS and in-hospital mortality (Figure-7a and 7b). 
Figure-7a  
 
Analysis of cardiogenic shock calculated from values of PCT and hsCRP at 24hours. 
ROC curve analysis with area under the curve and significance levels- 
Test Result 
Variables 
Area Under 
the Curve 
Std. 
Error
a
 
Asymptotic Sig.
b 
(p value) 
95% Confidence Interval 
Lower Bound Upper Bound 
PCT-24 0.895 0.078 0.001 0.742 1.000 
hsCRP-24 0.892 0.034 0.001 0.826 0.959 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
PCT-24 cut-off 0.43 ng/ml had 85.7% sensitivity and 86.5% specificity. 
hsCRP-24 cut-off 61.9 mg/L had 100% sensitivity and 82% specificity. 
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Figure-7b  
 
Analysis of in-hospital mortality calculated from values of PCT and hsCRP at 24hours. 
ROC curve analysis with area under the curve and significance levels- 
Test Result 
Variables 
Area Under 
the Curve 
Std. 
Error
a
 
Asymptotic Sig.
b 
(p value) 
95% Confidence Interval 
Lower Bound Upper Bound 
PCT-24 0.805 0.100 0.022 0.610 1.000 
hsCRP-24 0.900 0.034 0.003 0.832 0.968 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
PCT-24 cut-off 0.3675 ng/ml had 80% sensitivity and 81.3% specificity. 
hsCRP-24 cut-off 67.8 mg/L had 100% sensitivity and 81.3% specificity. 
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[F] CORRELATION OF PCT and hsCRP WITH LVEF 
 High level of inflammatory markers at 24 hours of admission was associated with 
lower left ventricular ejection fraction as depicted in Figure-8a and 8b. 
Figure-8a Association of PCT (at 24 hours) with LVEF 
The correlation coefficient (Spearman‟s rho) was -0.214 with p value of 0.036. 
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Figure-8b Association of hsCRP (at 24 hours) with LVEF 
The correlation coefficient (Spearman‟s rho) was -0.423 with p value of <0.001. 
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[G] CORRELATION OF PCT and hsCRP WITH ANGIOGRAPHIC 
FINDINGS 
Total 72 STEMI patients underwent primary PTCA or rescue PTCA; in these 
patients, total number of vessels involvement, total number of significant lesions and TIMI 
flow post angioplasty were determined. We correlated each of them with level of 
inflammatory markers. There was no significant difference in distribution of PCT and 
hsCRP level (both at admission and at 24 hours), based on stent (BMS / DES) use, as well 
as with number of arteries or lesions in angiography. 
When we compared PCT and hsCRP level with TIMI flow post PTCA, it was 
found that patients with TIMI flow <3 had higher elevation of both PCT and hsCRP at 24 
hours in comparison to patients with TIMI 3 flow. But, only PCT level at 24 hours (median 
value= 0.36 ng/ml) was significantly associated with TIMI flow <3 with p value of 0.017 
(Table-10 and Figure-9). PCT level >0.175 ng/ml at 24 hours was 100% sensitive and 65% 
specific to correlate with TIMI flow <3. 
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Table-10 Association of PCT and hsCRP with TIMI flow post angioplasty 
 
TIMI 3 
(n=64) 
TIMI <3 
(n=8) 
p-
value 
PCT-OA 0.0580 (0.0400/0.0865) 0.0550 (0.0243/0.0893) 0.572 
PCT-24 0.1090 (0.0670/0.2590) 0.3600 (0.2000/0.9100) 0.017 
hsCRP-OA 3.9 (1.86/6.99) 2.17 (1.13/5.62) 0.223 
hsCRP-24 25.60 (11.90/57.70) 66.1 (40.3/135.00) 0.111 
[PCT and hsCRP values shown as median value and 25
th
/75
th
 interquartile range] 
 
Figure-9 PCT and final TIMI flow post angioplasty 
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[H] CORRELATION BETWEEN PCT AND hsCRP 
 PCT level was correlated with that of hsCRP and significant correlation was found 
between the two inflammatory markers (Figure-10). Higher PCT level was associated with 
higher hsCRP level at 24hours. The correlation coefficient (Spearman‟s rho) was +0.503 
with p value of 0.01. 
 
Figure-10 Association of PCT and hsCRP (at 24 hours) 
 
  
 
 
 
 
Discussion 
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DISCUSSION 
 
Multiple modifiable and non-modifiable risk factors as well as risk scores have 
been developed to predict prognosis in patients presenting with acute STEMI. However, 
not all adverse events can be predicted by existing risk factors; particularly, development 
of cardiogenic shock (CS) which is one of the dreaded complications of STEMI. 
Subsequently, numerous biomarkers emerged as an indicator of adverse outcomes in 
patients of STEMI based on the hypothesis that myocardial infarction is associated with 
elevation of various inflammatory markers; particularly when complicated with CS.(4) 
Accumulated data suggests that Procalcitonin (PCT) as a marker of systemic inflammatory 
response in STEMI, may be a reliable predictor of development of cardiogenic shock and 
death in patients with acute myocardial infarction.(96) There is limited data regarding 
variation of PCT level with two main strategies of reperfusion in STEMI- primary PTCA 
and thrombolysis. Whether serum PCT level reliably reflects systemic inflammatory 
response in STEMI patients and how it varies between primary PTCA and thrombolytic 
groups is not studied so far. Our study demonstrates an insight in this matter. In addition, 
our data provides strong relationship between PCT and various clinical outcomes that will 
be valuable in guiding clinical use of this marker in patients of STEMI. 
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[A] COMPARISON OF PCT LEVEL BETWEEN THROMBOLYSIS 
AND PRIMARY PTCA 
In our study we intended to look for importance of PCT in patients with STEMI. 
We compared level of serum PCT at admission and at 24 hours between two groups based 
on reperfusion strategies- Thrombolysis and Primary PTCA. As primary PTCA is 
associated with complete revascularization with higher patency rate in comparison to 
thrombolysis, it provokes lesser systemic inflammatory response. Based on that we 
formulated the hypothesis that rise in serum PCT level should be more in thrombolysis 
group in comparison to primary PTCA group. At admission, PCT level was almost 
identical in both the groups but rise of PCT at 24 hours was significantly higher in 
thrombolytic group (median value- 0.1800 ng/ml) in comparison to primary PTCA group 
(median value- 0.0930 ng/ml). In addition, when we compared distribution of PCT level 
between the two groups by Wilcoxon–Mann–Whitney test, patients with thrombolysis 
tended to have larger values with p-value of 0.008. To the best of our knowledge, so far no 
study has reported variations of serum PCT level between Thrombolysis and Primary 
PTCA in patients of STEMI. Our study indirectly suggests that primary PTCA is 
associated with lesser systemic inflammatory activation in comparison to thrombolysis; 
supporting the fact that it is a better and preferred reperfusion strategy in STEMI. 
There can be a possibility that higher rise of inflammatory markers in thrombolysis 
group is due to inflammatory reaction to the thrombolytic agent streptokinase (STK). STK 
is a bacterial protein and administration of STK leads to an immunogenic response with the 
production of specific anti-streptokinase antibodies.(97) We analyzed variation of PCT 
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level in thrombolytic group to look into this matter and found that rise of PCT at 24 hours 
in patients with failed thrombolysis (median value- 0.2590 ng/ml) was much higher in 
comparison to patients with successful thrombolysis (median value- 0.1015 ng/ml), with p 
value of 0.001 by Wilcoxon–Mann–Whitney test. In fact, there was no difference in 
distribution of PCT level at 24 hours between primary PTCA and successful TLT patients; 
but there was significant rise of PCT at 24hours in failed TLT patients in comparison to 
primary PTCA group. These findings eliminate the possibility that inflammatory reaction 
to STK is responsible of rise of PCT; and establish PCT as a true marker for 
prognostication in patients with STEMI. 
 
[B] ASSOCIATION OF PCT WITH CARDIOGENIC SHOCK 
The secondary aim of our study was to correlate PCT with various in-hospital 
outcomes and to test association of PCT level with cardiogenic shock and mortality in 
patients of STEMI. There was marked elevation of PCT at 24 hours in patients who 
developed cardiogenic shock (median value- 1.5 ng/ml) in comparison to patients who 
didn‟t develop CS (medial value- 0.138 ng/ml); which is statistically significant with p 
value of 0.001. Based on ROC curve, PCT level at 24 hours >0.43 ng/ml was associated 
with CS with 85.7% sensitivity and 86.5%. 
In a study by Picariello et al(6), PCT values were significantly higher in CS patients 
in comparison to patients with uncomplicated AMI. In another retrospective study, it was 
observed that CS patients show high PCT level (>2 ng/ml), especially in the presence of 
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multi-organ failure even in the absence of signs of infections (cultures and clinical 
ﬁndings). The authors conclude that high PCT in CS patients do not necessarily indicate 
sepsis.(92) In a prospective study by Remskar et al(90) also showed that maximal PCT 
level remained almost normal (<0.5 ng/ml) in patients with uncomplicated AMI; while 
patients suffered from CS showed rise in PCT up to 5.24 ng/ml. 
 
[C] ASSOCIATION OF PCT WITH MORTALITY 
PCT was also a reliable marker to predict in-hospital mortality in our study. There 
was statistically significant elevation of PCT at 24 hours among patients who died during 
hospital stay (with median value- 0.44 ng/ml) in comparison to those who survived 
(median value- 0.1392 ng/ml). P-value was 0.022 calculated by Wilcoxon–Mann–Whitney 
test with alpha level of 0.05 and confidence level of 95%. Based on ROC curve, PCT level 
at 24 hours >0.3675 ng/ml showed 80% sensitivity and 81.3% specificity in prediction of 
in-hospital mortality. 
The prognostic role of PCT in AMI complicated by CS was evaluated by Andrie et 
al(7). The author concluded that on admission PCT level did not correlate with 30-day 
mortality, but PCT level at 24 hours (with cut-off of 1.23 ng/ml) was a very reliable 
predictor of 30-day mortality with sensitivity and specificity between 80-90%. In our 
study, PCT level at 24 hours >1 ng/ml was 95.6% specific to predict in-hospital mortality, 
but sensitivity was only 40%. In another study(98), high PCT level within 48 hours of 
admission was significantly associated with higher in-hospital and 6 months mortality. The 
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mean value of PCT within 48 hours among patients who died during hospitalization was 
0.588 ± 0.56 ng/ml, which is almost similar to the value we found in our study. The author 
concluded that higher PCT levels within 48 hours post-admission may reflect an 
inflammatory state that is associated with increased early and 6-month mortality. 
 
[C] PCT AND OTHER IN-HOSPITAL OUTCOMES 
 PCT level at 24 hours was a reliable marker to predict left ventricular ejection 
fraction in patients of STEMI. Higher level of PCT at 24 hours of admission was 
associated with lower left ventricular ejection fraction and it was statist ically significant (p 
value of 0.036) with correlation coefficient (Spearman‟s rho) was -0.214. It can be 
explained by the fact that more left ventricular dysfunction leads to cardiac failure and 
cardiogenic shock, which leads to elevation of various inflammatory markers in STEMI 
patients. 
Another interesting finding of the study was patients with TIMI flow <3 had higher 
elevation of both PCT and hsCRP in comparison to patients with TIMI 3 flow, again 
supporting the hypothesis that higher myocardial ischemia is associated with higher 
elevation of various inflammatory markers. PCT level at 24 hours (median value= 0.36 
ng/ml) was significantly associated with TIMI flow <3 (p value of 0.017). PCT level 
>0.175 ng/ml at 24 hours was 100% sensitive and 65% specific to correlate with TIMI 
flow <3. To the best of our knowledge, so far no study has reported such type of 
comparison previously. No significant correlation of PCT and hsCRP level (both at 
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admission and at 24 hours) was found with number of arteries or significant lesions in 
angiography. These findings suggest that PCT is a marker of acute inflammation rather 
than an indicator of chronic inflammatory atherosclerotic process. 
 
[D] CORRELATION BETWEEN PCT AND hsCRP 
 PCT level was correlated with that of hsCRP and significant correlation was found 
between the two inflammatory markers. Higher PCT level was associated with higher 
hsCRP level at 24hours. The correlation coefficient (Spearman‟s rho) was +0.503 with p 
value of 0.01.  hsCRP gave same prognostic information as PCT, but hsCRP level was 
unable to correlate with TIMI flow <3. Contrary to our findings, other studies done in the 
western countries(6,91) did not show any correlation of PCT with CRP in CS patients; 
which can be explained by the fact that timing of hsCRP measurement was different in 
those studies.  
 
  
 
 
 
 
Limitations 
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LIMITATIONS 
 
 We acknowledge certain limitations in our study: 
I. This is an observational study and not a randomized study; even though, 
consecutive patients of STEMI were recruited in the study to avoid selection bias. 
II. It is a single-center study with small number of patients. Larger multi-center study 
is required to represent the impact of study findings in true population. 
III. In thrombolysis group, 50 patients received Streptokinase (STK) as a thrombolytic 
agent; while only 1 patient got Tenecteplase (TNK). The association of 
inflammatory markers in this study cannot be linked with the outcomes in STEMI 
patients when TNK is used as a preferred thrombolytic agent. 
  
 
 
  
 
 
 
 
 
Summary and 
Conclusion 
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SUMMARY AND CONCLUSION 
 
The summary of main ﬁndings of our study was as follows: 
 PCT values increased significantly in all patients of STEMI in 24 hours of 
admission, in the absence of any sign of infection. Rise of PCT at 24 hours was 
significantly higher in thrombolytic group (median- 0.18 ng/ml) in comparison to 
primary PTCA group (median- 0.093 ng/ml). 
 There was significant rise of PCT at 24hours in failed TLT patients in comparison 
to successful TLT and primary PTCA group. 
 There was marked elevation of PCT at 24 hours in patients who developed 
cardiogenic shock (median- 1.5 ng/ml) and who died during hospital stay (median- 
0.44 ng/ml). 
 Based on ROC curve, PCT level at 24 hours >0.43 ng/ml was associated with CS 
with 85.7% sensitivity and 86.5% specificity. 
 PCT level at 24 hours >0.3675 ng/ml showed 80% sensitivity and 81.3% specificity 
in prediction of in-hospital mortality. 
 Higher level of PCT at 24 hours of admission was associated with lower left 
ventricular ejection fraction. 
 PCT level at 24 hours was significantly associated with TIMI flow <3 after primary 
or rescue PTCA. But there was no significant correlation of PCT with number of 
arteries or significant lesions in angiography. 
64 
 
 Rise in level of PCT showed significant correlation with rise of hsCRP level. 
 
CONCLUSION: 
Our study strongly suggests the prognostic role of procalcitonin in patients of 
STEMI for future risk prediction. Higher level of procalcitonin at 24 hours is 
significantly associated with cardiogenic shock in the absence of any infection. In fact, 
PCT is a very reliable predictor of in-hospital mortality with high sensitivity and 
specificity, and it correlates with hsCRP. In patients of STEMI, systemic inﬂammatory 
response is better reflected by PCT; and it indirectly suggests that primary PTCA is 
associated with lesser systemic inflammatory activation in comparison to thrombolysis. 
Potential therapeutic interventions modulating the systemic inflammatory reaction have 
to be analyzed in further studies. 
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Appendices 
Appendix I: Abbreviations 
 
ACS: Acute Coronary Syndrome 
AMI: Acute Myocardial Infarction 
AST: Aspartate aminotransferase 
BMS: Bare-metal Stent 
BNP: B-natriuretic peptides 
CAD: Coronary Artery Disease 
CHD: Coronary Heart Disease 
CK: Creatine Kinase 
CREATE registry: Treatment and outcomes of acute coronary syndromes in India 
registry 
CRP: C-reactive protein 
CS: Cardiogenic Shock 
cTn: Cardiac Troponin 
cTnI & cTnT: Cardiac Troponin I & T 
DES: Drug-eluting stent 
DM: Diabetes mellitus 
ECG: Electrocardiogram 
FDA: Food and Drug Administration 
GDF-15: Growth Differentiation Factor-15 
GRACE registry: Global Registry of Acute Coronary Events registry 
GUSTO trial: Global Utilization of Streptokinase and Tissue Plasminogen Activator for 
Occluded Arteries trial 
HF: Heart failure 
hFABP: Heart Fatty Acid Binding Protein 
hsCRP: High-sensitivity C-reactive protein 
hsCRP-OA & hsCRP-24: hsCRP level at the time of admission & at 24 hours, 
respectively 
HTN: Hypertension 
IMA: Ischemia Modified Albumin 
LBBB: Left bundle branch block 
LDH: Lactate dehydrogenase 
LDL: Low-density Lipoprotein 
LV: Left ventricle 
LVEF: Left Ventricle Ejection Fraction 
MPO: Myeloperoxidase 
MI: Myocardial Infarction 
NSTEMI: Non-ST segment Elevation Myocardial Infarction 
NT-proBNP: Amino-terminal portion of the pro-BNP peptide 
PaPPA: Pregnancy associated Plasma Protein A 
PCI: Percutaneous Coronary Intervention 
PCT: Procalcitonin 
PCT-OA & PCT-24: Procalcitonin level at the time of admission & at 24 hours, 
respectively 
PTCA: Percutaneous Transluminal Coronary Angioplasty 
ROC curve: Receiver operating characteristic curve 
sCD40L: Soluble CD40 Ligand 
SIRS: Systemic Inflammatory Response Syndrome 
STEMI: ST segment Elevation Myocardial Infarction 
STK: Streptokinase 
TIMI: Thrombolysis In Myocardial Infarction 
TLT: Thrombolytic therapy 
UA: Unstable Angina 
  
Comparative Study of Serum Procalcitonin Level in STEMI 
Patients Undergoing Primary PTCA v/s Thrombolysis & 
to Correlate with In-hospital Outcomes 
 
 
 
 
 
 
 
History & Examination- 
 
h/o EA h/o ACS h/o PTCA/CABG 
NYHA 
Class- 
duration-   
 
PR 
(/min) 
BP 
(mmHg) 
  
 
Cardiogenic shock Y / N 
 
 
Name Hospital no DOA 
   
Age Sex Ht (cm) Wt (kg) BMI 
     
HTN DM Smoking f/h/o 
IHD 
Postmenopausal 
state 
N Y yrs- N Y yrs- N Ex Y Pack 
yrs- 
N Y N Y 
Presenting c/o WP(hrs) 
  
Killip’s class 
O/A- Max- 
Serial no- 
Appendix II: Clinical Research Form 
Group- PTCA / TLT 
ECG, CXR & ECHO- 
 
 
Complications- 
 
Outcomes 
Uneventful Post-MI angina Re-infarction Death (CAUSE) 
 
Blood Ix- 
Hb TC DC RBS FBS HBA1C Creat TC/TG/HDL/LDL ESR 
         
 
 O/A 24 hrs 
Procalcitonin   
CRP   
E 
C 
G 
ECG diagnosis- RBBB 
/ 
LBBB 
ST resolution 
>70% 
C 
X 
R 
 
Y N 
E 
C 
H 
O 
LVEF MR LVDD/S MV E/A RWMA 
     
Mechanical complications Electrical complications Others 
PMR VSR FVR VT/VFi CHB    TPI- Y/N AFi  
 O/A  
Troponin T   
CKMB mass   
 Treatment- 
THROMBOLYTIC 
THERAPY 
TIMI risk score- 
Agent- STK / TNK 
Result- successful / failed 
Anticoagulation- UFH / LMWH / Fondaparinux 
Rescue PTCA- Y / N     indication- 
 
ASP/CLP/STATIN/BB/ACEI/NITRATES/DOPA/DOBUT/ 
NORAD/LASIX/ALD/Others- 
 
PRIMARY 
PTCA 
(+ Angio profile) 
Infarct related artery- LM / LAD / LCX / RCA 
Total artery with significant lesion- 1 / 2 / 3 / LM 
Total no of significant lesion- 
TIMI thrombus grade- 0 / 1 / 2 / 3 / 4 / 5 
Mechanical thrombosuction- Y / N 
Stent used- BMS / DES 
TIMI flow in culprit artery- Before PTCA:           After PTCA: 
Tirofiban- Y / N        Duration- 
Anticoagulation- UFH / LMWH / Fondaparinux 
ASP/CLP/STATIN/BB/ACEI/NITRATES/DOPA/DOBUT/ 
NORAD/LASIX/ALD/Others- 
 
 
  
Appendix III: Master Data Sheet 
 
GLOSSARY FOR MASTER CHART: 
SN- Serial Number 
GN- Group Number [P- primary PTCA group, T- thrombolytic group, R- rescue PTCA 
group] 
S- Sex [M- male, F- female] 
A- Age (in years) 
HT- Hypertension (Y- yes, N- no) 
DM- Diabetes Mellitus (Y- yes, N- no) 
Sk- Smoking (Y- yes, N- no) 
WP- Window Period (in hours) 
P- Pulse rate (per minute) 
BP- (systolic) Blood pressure (mmHg) 
TIMI- TIMI risk score 
ECG- AW- anterior wall, AWr- anterior wall with RBBB, IWRV- inferior wall + right 
ventricular, IWPL- inferior wall ± posterior/lateral wall 
Ki- Killip’s class 
CS- Cardiogenic shock (Y- yes, N- no) 
EF- Ejection fraction (%) 
Oc- Outcome (S- survived, D- death) 
Hb- Hemoglobin (g/dl) 
TLC- Total leukocyte count (per cumm) 
RBS- Random blood sugar (mg %) 
HbA- HbA1C 
Cr- serum Creatinine (mg %) 
GFR- estimated Glomerular Filtration Rate by CKD-EPI formula (mL/min/1.73 m2) 
TC- Total cholesterol 
TG- Triglyceride 
HDL- High density lipoprotein 
LDL- Low density lipoprotein 
PCT-OA- Procalcitonin at admission (ng/ml) 
PCT-24- Procalcitonin at 24 hours (ng/ml) 
CRP-OA- hsCRP at admission (mg/L) 
CRT-24- hsCRP at 24hours (mg/L) 
TLa- Thrombolytic agent (STK- streptokinase, TNK- tenecteplase) 
TLr- Thrombolysis result (S- successful, F- failed) 
Res- Rescue PTCA (Y- yes, N- no) 
IRA- Infarct related artery (LM- left main, LAD- left anterior descending, RCA- right 
coronary artery, LCX- left circumflex) 
NoV- Number of Vessels with significant lesion 
NoL- Number of Lesions (significant) 
Stent- Stent used (DES- drug eluting stent, BMS- bare metal stent) 
Tpre- TIMI flow pre-PTCA 
Tpo- TIMI flow post-PTCA 
 
SN GN Sx Ag HT DM Sk WP P BP TIMI ECG Ki CS EF Oc Hb TLC RBS HbA Cr GFR TC TG HDL LDL PCT-OA PCT-24 CRP-OA CRP-24 TLa TLr Res IRA NoV NoL Stent Tpre Tpo
1 P1 M 74 Y N N 2 80 110 4 AW 1 N 45 S 10.5 8400 ─ 4.9 1.08 67.3 133 58 34 96 0.0408 0.0847 3.83 3.16 LAD 1 1 DES 0 3
2 P2 M 60 Y Y N 5 94 106 5 AW 2 N 41 S 14 13900 223 8 1.75 41.4 172 63 55 118 0.0814 0.5122 0.7 49.6 LAD 1 1 DES 0 3
3 P3 M 82 Y N N 4 80 150 6 AW 1 N 45 S 12.8 13300 119 5.8 0.75 85.4 120 76 37 79 0.0741 0.0852 1.09 8.31 LAD 3 3 DES 0 3
4 P4 M 65 Y N Y 3.5 90 80 6 IWRV 1 N 52 S 13.9 14400 221 6.2 1.03 75.9 121 67 30 68 0.1167 0.103 1.3 5.68 RCA 2 2 BMS 0 3
5 P5 M 61 N Y N 4.5 66 110 2 IWPL 1 N 56 S 11.3 10400 155 8.3 1.18 66.2 189 104 37 126 0.097 0.0735 2.26 6.11 RCA 2 2 DES 1 3
6 P6 F 70 N Y N 2.5 65 170 5 IWRV 2 N 45 S 15 10200 362 11.3 1.42 37.3 386 684 30 228 0.187 0.407 9.31 8.98 RCA 3 5 POBA 0 3
7 P7 M 57 N N Y 8.5 77 100 1 IWPL 1 N 55 S 14.2 8300 195 5.9 1.12 72.5 161 57 37 108 0.0576 0.5146 1.25 21.3 LCX 1 1 DES 0 3
8 P8 M 56 N N Y 2 80 160 1 AW 1 N 41 S 16.3 16800 ─ 6.1 1.26 63.3 234 134 42 156 0.0441 0.1487 2.01 11.9 LAD 1 1 DES 0 3
9 P9 F 70 Y Y N 3 76 120 4 AW 1 N 41 S 14.3 13100 106 6.9 1.17 47.2 222 74 59 139 0.04 0.2612 6.06 40.3 LAD 1 1 DES 1 2
10 P10 M 40 N N Y 3 84 140 0 IWRV 1 N 45 S 19.4 8100 174 5.7 1.06 87.4 166 85 32 108 0.0686 0.1406 9.54 8.12 RCA 2 2 BMS 0 3
11 P11 M 62 N N N 26 80 140 1 IWPL 1 N 48 S 13.7 13200 136 6.4 1.13 69.3 163 100 52 88 0.1142 0.17 34.5 100 RCA 1 2 BMS 0 3
12 P12 F 44 Y N N 4.5 54 110 3 IWRV 1 N 52 S 11.6 11400 142 5.8 1.17 56.6 267 135 69 164 0.08 0.19 4.74 34.7 RCA 1 1 BMS 0 3
13 P13 M 50 N N Y 15 78 120 2 AWr 1 N 43 S 13.7 11100 115 5.2 0.85 101.6 166 67 36 106 0.06 0.05 4.12 19.8 LAD 2 2 BMS 0 3
14 P14 M 65 N Y Y 18 60 100 4 IWRV 1 N 48 S 14.7 7500 211 8.7 1.57 45.6 110 82 35 60 0.03 0.04 0.45 3.6 RCA 2 2 DES 0 3
15 P15 M 40 Y N Y 6 62 120 2 IWRV 1 N 45 S 13.4 6900 76 5.3 1.13 80.9 258 82 33 190 0.04 0.03 5.8 12.8 RCA 3 5 BMS 0 3
16 P16 M 50 Y Y N 4.5 98 100 3 AW 1 N 44 S 15.3 13200 165 7.2 0.67 112 179 272 31 112 0.0913 0.11 1.3 8.26 LAD 1 1 BMS 0 3
17 P17 M 58 N N N 4 84 140 2 AW 1 N 46 S 17.4 5300 175 5.8 1.19 66.9 124 103 28 76 0.05 0.09 0.78 0.61 LAD 2 2 DES 0 3
18 P18 M 44 N Y Y 4.5 120 90 10 AW 4 Y 30 D 17.6 17300 118 7.2 1.64 50.1 199 248 30 134 0.0265 1.5 18.7 100 LAD 3 4 DES 0 3
19 P19 M 67 Y N N 5 80 100 7 AW 2 N 35 S 15 17200 148 5.8 1.21 61.6 201 60 44 138 0.0888 0.169 8.96 100 LAD 3 4 BMS 1 3
20 P20 F 62 N N N 1 60 140 2 AW 1 N 37 S 12.5 10500 147 5.9 0.91 67.6 255 75 50 185 0.056 0.057 15.9 16.6 LAD 1 1 DES 0 3
21 P21 M 76 Y N Y 8 72 90 11 AW 4 Y 28 D NA NA 242 ─ 1.7 38.3 ─ ─ ─ ─ 0.024 ─ 4.3 ─ LAD 3 3 DES 0 1
22 P22 F 60 N N N 10 80 130 3 AW 1 N 40 S 12.8 14500 94 5.7 1.35 42.6 101 83 46 96 0.03 0.05 1.87 5 LAD 1 2 DES 0 3
23 P23 M 54 N N Y 2.5 80 140 1 AW 1 N 41 S 14.2 11700 101 6.1 1.23 66.1 176 162 23 104 0.07 0.07 12.4 25.6 LAD 1 1 DES 1 3
24 P24 M 40 Y Y N 6 76 100 3 AW 1 N 42 S 15.9 15300 119 7.1 2 40.5 179 168 33 123 0.06 0.058 6.91 32.8 LAD 2 2 DES 0 3
25 P25 M 50 N N Y 3.5 74 110 0 IWRV 1 N 45 S 17.9 15000 166 6.4 1.23 68 ─ ─ ─ ─ 0.06 0.06 0.9 1.65 RCA 2 3 BMS 0 3
26 P26 M 69 N N N 14 96 100 3 IWRV 1 N 55 S 12.3 NA 131 6.1 0.94 82.4 151 112 29 113 0.04 0.06 2.6 17.4 RCA 3 4 POBA 0 3
27 P27 M 48 Y Y N 14 80 120 3 AW 1 N 36 S 13.8 11600 202 8 1.28 65.7 203 95 39 159 0.0245 0.0495 2.06 12.5 LAD 1 1 DES 0 3
28 P28 M 40 N N Y 0.5 86 120 1 AW 1 N 50 S 16 7900 111 6.2 1.17 77.5 183 99 42 107 0.04 0.0465 4.9 5.59 LAD 2 2 DES 1 3
29 P29 M 36 N N Y 6 100 150 4 AW 2 N 41 S 16.8 18400 122 6.4 1.13 83.2 151 185 43 83 0.048 0.197 6.41 88.5 LAD 1 1 BMS 1 3
30 P30 F 62 N Y N 3.5 72 140 2 IWPL 1 N 50 S 12.3 10900 297 10.4 1.19 48.9 238 181 32 176 0.0946 0.163 11 30.2 LCX 3 5 DES 0 3
31 P31 M 54 Y N N 1 76 150 2 AW 1 N 42 S 13.1 7700 123 5.7 1.25 64.9 145 171 32 184 0.0407 0.067 5.54 23.3 LAD 2 3 DES 0 3
32 P32 M 66 N N N 18 82 110 4 AW 1 N 37 S 13.2 14700 137 5.9 1.2 62.6 133 61 51 72 0.031 0.0336 10.5 100 LAD 3 4 DES 0 3
33 P33 M 45 Y Y Y 1 80 170 2 AW 1 N 45 S 15.1 7400 306 10.1 1.18 74.1 176 159 28 125 0.026 0.09 1.68 12.8 LAD 2 2 DES 0 3
34 P34 M 38 Y N Y 1.5 0 0 9 AWr 4 Y 25 D 24 17600 178 ─ 1.7 50 ─ ─ ─ ─ 0.216 ─ 5.3 ─ LM 1 1 POBA 0 3
35 P35 M 40 Y Y N 8 126 160 7 AWr 2 N 45 S 17 15900 290 9.1 1.21 74.4 189 214 33 117 0.1726 0.54 2 284 LAD 1 3 DES 1 2
36 P36 M 41 N Y Y 18 70 140 2 IWPL 1 N 55 S 14.7 NA 278 11.6 1.14 79.4 141 73 28 87 0.02 0.03 9.85 37.7 LCX 2 2 DES 0 3
37 P37 M 56 N N N 3.5 72 110 1 AW 1 N 47 S 13 13300 184 6 1.17 69.3 170 96 33 117 0.038 0.073 3.09 34.6 LAD 1 1 DES 0 3
38 P38 M 74 N Y N 2.5 8 170 4 IWRV 1 N 48 S 12.6 NA 515 13.7 1.76 37.3 111 75 27 61 0.06 0.099 2.24 6.85 RCA 2 3 DES 1 3
39 P39 M 61 Y Y N 4.5 68 110 2 IWPL 1 N 53 S 11.2 11800 264 7.6 1.1 72.1 125 79 30 87 0.058 0.083 0.95 7.19 LCX 2 2 DES 0 3
40 P40 M 35 N N Y 2 70 94 6 AW 2 N 49 S 12.8 17000 111 5.2 0.9 110.3 115 83 29 73 0.042 0.062 1.07 3.83 LAD 1 1 BMS 0 3
41 P41 M 50 N Y N 4.5 96 130 3 AW 1 N 40 S 15.8 11300 261 ─ 1.16 73 178 159 29 121 0.058 0.07 5.42 22.8 LAD 2 2 DES 0 3
42 P42 M 46 N Y Y 5 120 80 10 AWr 4 Y 36 S 18.4 18700 356 8.9 1.2 72.1 208 176 41 155 0.204 6.3 2.535 214 LAD 2 2 DES 0 3
43 P43 M 47 N Y Y 2 82 130 4 AW 2 N 40 S 12.9 13300 100 6.8 1.16 74.6 182 74 26 124 0.069 0.78 45 230 LAD 3 3 DES 1 3
44 P44 M 48 N N Y 3.5 120 110 5 AW 2 N 40 S 15.8 11700 139 5.3 1.2 71.1 112 75 32 68 0.191 0.204 3.97 22.1 LAD 1 1 DES 0 3
45 P45 M 37 N Y Y 1 55 100 1 IWRV 1 N 44 S 14.8 11000 166 7 1.06 89.2 166 120 27 121 0.052 0.109 2.21 19.9 RCA 1 2 DES 0 3
46 P46 M 90 N Y N 10 80 110 6 AW 1 N 39 S 10 8900 144 8.8 0.91 73.9 139 67 48 78 0.05 0.077 2.67 28.7 LAD 2 2 DES 0 3
47 P47 M 62 N Y N 10 70 110 3 AWr 1 N 35 S 12.8 17300 78 7.4 1.25 61.3 247 138 45 176 0.07 0.36 2.33 135 LAD 1 1 DES 0 2
48 P48 M 43 N N N 1.5 94 136 1 AW 1 N 36 S 13.6 13700 161 ─ 1.18 75.1 163 99 39 96 0.069 0.167 5.99 37.1 LAD 1 1 BMS 0 3
49 P49 M 47 N N Y 8 110 120 5 IWPL 4 Y 40 D 15.3 20800 139 5.1 1.8 43.8 161 173 17 103 0.15 0.44 11.5 134 LCX 2 3 DES 0 3
50 P50 M 75 N Y N 6 58 130 5 IWRV 1 N 45 S 11.9 11700 127 6.6 1.17 60.6 163 168 26 107 0.056 0.083 1.92 13.3 RCA 3 4 BMS 0 3
51 P51 M 52 N N Y 2 100 110 1 AW 1 N 38 S 16 19900 192 6 1.17 71.3 210 197 27 156 0.087 0.211 2.23 51.1 LAD 1 1 BMS 0 3
SN GN Sx Ag HT DM Sk WP P BP TIMI ECG Ki CS EF Oc Hb TLC RBS HbA Cr GFR TC TG HDL LDL PCT-OA PCT-24 CRP-OA CRP-24 TLa TLr Res IRA NoV NoL Stent Tpre Tpo
52 T1 M 42 N N Y 4.5 80 120 1 IWRV 1 N 47 S 13.8 15800 161 6.1 1.37 63.2 192 132 26 144 0.1173 0.178 10.3 20.6 STK S N
53 T2 F 69 Y N N 3 82 110 4 IWRV 1 N 50 S 12.9 11900 195 6.1 0.83 71.9 175 103 45 104 0.0352 0.0809 6.04 49.3 STK S N
54 T3 M 41 Y N N 12 78 110 3 AW 1 N 36 S 13.7 13600 178 ─ 0.97 96.6 131 184 31 74 0.1454 0.1275 1.75 31.3 STK F N
55 T4 M 60 Y Y N 3 100 130 2 AW 1 N 35 S 14 16000 289 7.1 1.7 42.9 213 211 54 121 0.1319 0.303 10.9 55.7 STK S N
56 T5 F 79 Y Y N 10 84 140 9 AW 3 N 35 S 12.7 28500 207 7.6 1.2 42.9 301 258 40 224 0.02 0.04 6.14 18.6 STK S N
57 T6 M 43 N N Y 3.5 110 110 5 AW 2 N 35 S 16.5 26900 186 ─ 1.95 40.9 204 275 27 134 0.043 0.216 8.09 45.5 STK F N
58 T7 M 39 N N Y 1 70 120 1 AW 1 N 40 S 17.4 NA 137 ─ 1.45 60.2 ─ ─ ─ ─ 0.065 0.1472 5.8 18.3 STK S N
59 T8 F 75 Y Y N 12 0 0 14 AW 4 Y 30 D 12.2 15400 379 ─ 1.8 27.1 262 106 54 166 0.02 6.4 47.5 100 STK F N
60 T9 F 70 Y Y N 8 10 120 10 AW 4 Y 30 D 11.4 10900 134 8.3 0.97 59.2 198 213 30 132 0.04 0.1 5.43 69.5 STK F N
61 T10 M 76 N Y N 4 80 100 7 AW 2 N 45 S 12.7 2200 334 11.3 1.8 35.8 178 184 29 132 0.07 0.14 18.2 24.1 STK S N
62 T11 M 50 Y N N 3 80 140 1 IWPL 1 N 40 D 17.7 3100 128 ─ 1.58 50.3 ─ ─ ─ ─ 0.024 ─ 0.69 ─ STK F N
63 T12 M 63 N N Y 3.5 102 120 5 AWr 2 N 40 S 14.5 13200 110 ─ 0.97 82.7 233 186 41 160 0.02 0.045 2.18 48.4 STK S N
64 T13 M 52 Y Y Y 11 98 160 3 AW 1 N 45 S 14.6 NA 308 ─ 1.28 63.9 191 169 25 150 0.03 0.138 4.12 33.6 STK S N
65 T14 M 61 N N Y 4 100 110 0 IWRV 1 N 38 S 10.9 10500 169 5.7 1.18 66.2 117 49 36 70 0.06 0.151 1.43 23.5 STK S N
66 T15 M 73 Y N N 4 70 110 4 IWRV 1 N 51 S 11.6 11300 135 6 2.72 22.2 116 45 50 51 0.047 0.996 0.21 23.9 STK S N
67 T16 F 81 N N N 3.5 48 0 7 IWRV 2 N 45 S 10.8 11700 224 ─ 1.35 36.7 91 92 41 38 0.076 0.612 9.84 41 STK F N
68 T17 M 65 N Y N 2.5 130 70 11 AW 4 Y 30 D 11.9 13100 ─ ─ 1.77 39.4 ─ ─ ─ ─ 0.06 ─ 23.2 ─ STK F N
69 T18 M 38 N N Y 3 76 140 1 AW 1 N 42 S 18.5 10600 126 5.7 0.92 105.1 109 123 36 63 0.038 0.065 3.09 79.8 STK S N LAD 1 1 BMS 3 3
70 T19 F 66 N Y N 4.5 78 220 8 AW 2 N 37 S 11.2 16800 181 7.8 1.34 41.2 206 157 57 133 0.032 0.1 10.9 38.3 STK F N
71 T20 M 57 N Y N 4 118 70 10 AWr 4 Y 30 D 9.7 12400 252 ─ 1.17 68.8 129 52 27 103 0.032 ─ 0.61 ─ STK F N
72 T21 M 45 N N N 2 103 130 3 AW 1 N 47 S 14.6 13200 71 5.3 1 90.5 172 99 34 117 0.028 0.084 1.58 45.2 STK S N
73 T22 M 62 Y N Y 2 70 110 2 IWRV 1 N 53 S 8 15400 142 6.3 1.25 61.3 108 54 127 65 0.09 1.19 58.5 238 STK F N
74 T23 M 53 N N N 5 82 140 2 AW 1 N 44 S 15.6 11000 114 5.6 1.34 60.1 175 98 34 117 0.03 0.119 0.6 35.3 STK S N
75 T24 M 45 N N N 14 84 120 2 AW 1 N 39 S 11.7 14800 112 5.6 1.21 71.9 101 32 32 58 0.033 0.203 3.2 42 STK F N
76 T25 M 33 N N N 4.5 98 160 2 AW 1 N 45 S 15.4 NA 131 5.9 1.16 82.3 261 525 28 155 0.05 0.065 1.31 31.2 STK S N
77 T26 F 59 Y N N 2.5 78 130 2 IWRV 1 N 50 S 10.9 10700 108 6.4 0.95 65.6 260 197 34 165 0.04 0.06 9.88 100 STK S N
78 T27 F 63 Y Y N 12 66 90 8 IWPL 4 Y 35 D 9.6 11000 492 ─ 2.04 25.3 ─ ─ ─ ─ 0.11 ─ 21 ─ STK F N
79 T28 M 60 N N Y 6 60 110 1 IWRV 1 N 49 S 12.4 9600 101 5.4 1.11 71.8 120 60 33 81 0.047 0.54 0.167 23.6 STK F N
80 T29 M 60 N N Y 2 80 140 1 AW 1 N 44 S 10.4 7700 ─ ─ 0.93 88.9 136 74 32 86 0.02 0.36 1.2 18.2 STK S N
81 T30 M 73 N Y N 5 72 140 4 IWPL 1 N 44 S 12.3 7800 159 8.4 1.32 53.1 131 88 27 88 0.02 0.078 1.16 20.4 STK S N LCX 3 7 DES 2 3
82 T31 M 54 N Y N 1 100 100 2 AW 1 N 43 S 14 9200 132 ─ 0.88 97.4 186 111 30 117 0.044 0.068 0.74 38.2 STK S N LAD LM+2 3 2
83 T32 M 50 Y Y N 2 90 110 4 AWr 2 N 30 S 14.4 14300 319 ─ 1.14 74.6 ─ ─ ─ ─ 0.0701 0.1392 4.75 47.1 TNK F N
84 R1 M 61 Y N Y 4.5 80 140 3 AW 1 N 30 S 14.2 12500 136 5.8 1.56 47.2 133 85 45 75 0.1084 0.259 66.2 100 STK F Y LAD 1 1 DES 0 3
85 R2 M 44 N N Y 5 72 100 2 AW 1 N 35 S 14.3 7600 148 5.8 1.18 74.6 230 91 40 164 0.046 0.1477 4.79 24 STK F Y LAD 2 2 BMS 0 3
86 R3 M 55 Y N Y 5 70 100 2 IWPL 1 N 49 S 14.8 13800 187 6 1.2 67.7 175 227 32 99 0.05 0.42 1.83 69.5 STK F Y LCX 2 2 BMS 0 3
87 R4 F 53 N Y N 3 96 130 3 AW 1 N 33 S 13.2 12500 191 7.4 1.13 55.4 185 164 32 120 0.02 0.18 0.98 93.9 STK F Y LAD 3 5 BMS 2 2
88 R5 M 52 Y N N 1 80 130 4 AW 3 N 33 S 15.3 12400 143 5.5 1.4 57.4 196 222 33 122 0.085 0.1001 7.01 57.7 STK F Y LAD 2 2 BMS 0 3
89 R6 M 47 N N N 11 62 100 1 IWRV 1 N 46 S 14.9 13000 84 ─ 1.06 83.2 165 56 37 122 0.05 0.03 1.97 50.5 STK F Y RCA 2 2 DES 0 3
90 R7 M 63 N Y N 8.5 94 100 5 AWr 4 Y 34 S 17 12200 360 10.9 1.1 71.1 173 189 33 118 0.036 1.057 0.455 100 STK F Y LAD 2 2 BMS 2 3
91 R8 M 60 N Y Y 3 92 144 4 AW 2 N 38 S 16.1 19200 271 ─ 1.58 46.8 225 164 45 144 0.09 0.91 1.56 55.3 STK F Y LAD 2 2 DES 0 1
92 R9 M 60 Y N Y 8 110 160 5 AW 1 N 40 D 11 17900 126 ─ 1.16 68.1 170 95 40 90 0.06 0.375 4.81 199 STK F Y LAD 1 1 DES 2 3
93 R10 M 39 Y Y Y 3 116 160 4 AW 1 N 38 S 15 8100 274 8.2 0.98 96.7 262 1227 35 82 0.06 0.257 3.96 37.8 STK F Y LAD 1 1 BMS 1 3
94 R11 M 59 N Y Y 4.5 60 150 3 AWr 1 N 41 S 13.8 17600 225 6.8 1.36 56.6 195 138 29 148 0.038 0.262 6.56 30 STK F Y LAD 1 1 BMS 2 3
95 R12 M 52 N Y Y 7 80 120 3 AW 1 N 44 S 14.8 8500 219 9 1.11 75.9 239 865 25 80 0.02 0.464 1.57 19.6 STK F Y LAD 3 3 BMS 2 3
96 R13 M 53 N Y N 5.5 72 140 2 IWPL 1 N 45 S 13.5 9500 466 11 1.48 53.3 222 183 47 147 0.12 0.533 1.85 91.5 STK F Y LCX 2 2 DES 2 3
97 R14 M 48 N Y Y 4 120 120 5 AW 1 N 35 S 17 20600 329 10.1 1.18 72.5 223 300 31 155 0.07 0.265 6.59 51.5 STK F Y LAD 2 2 BMS 2 3
98 R15 M 47 N Y N 7 104 130 7 IWPL 2 N 51 S 10.5 15600 208 6.7 1.1 79.5 142 89 37 86 0.025 0.2 0.583 22 STK F Y LCX 1 1 POBA 2 2
99 R16 M 38 N Y Y 8 102 120 5 AW 1 N 42 S 14.7 8200 255 10.1 1.21 75.5 143 95 41 80 0.03 0.134 17.7 45.7 STK F Y LAD 3 4 DES 2 3
100 R17 M 40 N N N 4.5 86 106 1 IWRV 4 Y 42 S 14.8 1220 92 4.9 0.81 111.2 125 44 32 86 0.087 5.19 6.42 66.1 STK F Y RCA 1 1 BMS 0 1
101 R18 M 72 Y Y Y 6 86 110 5 AW 1 N 37 S 11.9 11500 219 7.4 1.79 37 167 84 36 102 0.189 0.48 190 220 STK F Y LAD 2 3 DES 2 3
102 R19 M 52 N Y Y 4.5 74 130 3 AW 1 N 42 S 15.3 7700 301 13.9 1.52 51.9 235 317 29 147 0.103 0.212 2.89 57 STK F Y LAD 1 1 BMS 0 3
